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BACKGROUND: The aim of this study was to investigate the safety of neoadjuvant chemoradiation using radiotherapy (RT) combined
with concurrent capecitabine and irinotecan for locally advanced rectal cancer before surgery.
METHODS: Forty-six patients were recruited and treated on the basis that MRI scanning had shown poor-risk tumours with threatening
(p1mm) or involvement of the mesorectal fascia. Conformal RT was given using 3 or 4 fields at daily fractions of 1.8Gy on 5 days
per week to a total dose of 45Gy. Concurrently oral capecitabine was given twice daily throughout radiotherapy continuously from
days 1 to 35 and intravenous irinotecan was given once per week during weeks 1 to 4 of RT. Dose levels were gradually escalated as
follows. Dose level 1: capecitabine 650mgm
 2 b.i.d. and irinotecan 50mgm
 2; Dose level 2: capecitabine 650mgm
 2 b.i.d. and
irinotecan 60mgm
 2; Dose level 3: capecitabine 825mgm
 2 b.i.d. and irinotecan 60mgm
2; Dose level 4: capecitabine 825mgm
 2
b.i.d. and irinotecan 70mgm
 2.
RESULTS: Diarrhoea (grade 3, no grade 4) was the main serious acute toxicity with lesser degrees of fatigue, neutropenia, anorexia and
palmar-plantar erythrodysesthesia. The recommended dose for future study was dose level 2 at which 3 of 14 patients (21%)
developed grade 3 diarrhoea. Postoperative complications included seven pelvic or wound infections and two anastomotic and two
perineal wound dehiscences. There were no deaths in the first 30 days postoperatively. Of 41 resected specimens, 11 (27%) showed
a pathological complete response (pCR) and five (12%) showed an involved circumferential resection margin (defined as p1mm).
The 3-year disease-free survival (intent-to-treat) was 53.2%.
CONCLUSION: In patients with poor-risk MRI-defined locally advanced rectal cancer threatening or involving the mesorectal fascia,
preoperative chemoradiation based on RT at 45Gy in 25 daily fractions over 5 weeks with continuous daily oral capecitabine at
650mgm
 2 b.i.d. days 1–35 and weekly IV irinotecan at 60mgm
 2 weeks 1–4, provides acceptable acute toxicity and
postoperative morbidity with encouraging response and curative resection rates.
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The mainstay of curative treatment for rectal cancer is surgery
and the surgical technique of total mesorectal excision (TME),
wherein meticulous sharp dissection is carried out in the plane of
the mesorectal fascia, has been shown to reduce the chance of
local recurrence (MacFarlane et al, 1993; Kapiteijn et al, 2001).
Perioperative RT can reduce the chance of local recurrence
following rectal cancer surgery (Colorectal Collaborative Group,
2001). The FFCD 9203 and EORTC 22921 trials have shown that
for operable rectal cancer combined fluoropyrimidine chemo-
therapy and long-course RT confers an advantage in terms of
reducing local pelvic recurrence compared with RT alone (Bosset
et al, 2006; Gerard et al, 2006). A large randomised trial
has definitively shown that preoperative chemoradiation (CRT)
reduces local recurrence in operable rectal cancer compared with
postoperative CRT (13 vs 6%), with reduced acute and late toxicity
(Sauer et al, 2004).
Involvement of the circumferential resection margin (CRM) has
been shown to be an important, independent prognostic factor,
resulting in high rates of local recurrence (Quirke et al, 1986; Wibe
et al, 2002), distant metastases (Hall et al, 1998; Mawdsley et al,
2005) and worse survival (Birbeck et al, 2002; Nagtegaal and
Quirke, 2008), even after TME surgery (Marijnen et al, 2003).
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histological CRM may be positive including direct or disconti-
nuous tumour spread, lymph node spread, lymphovascular spread
and perineural spread (Nagtegaal and Quirke, 2008). CRM
positivity is also strongly related to the quality of surgery
(Nagtegaal et al, 2002; Quirke et al, 2009).
In the United Kingdom and increasingly elsewhere, preoperative
MRI scanning of the pelvis is viewed as the gold standard for
judging threatening or involvement of the mesorectal fascial
potential surgical TME resection plane. In 311 patients with
operable rectal cancer who were shortly due to undergo surgery,
the MERCURY trial showed that preoperative MRI has high
accuracy, negative predictive value and specificity in the identi-
fication of a potentially involved CRM (MERCURY Study Group,
2006).
Approximately 20–30% of rectal cancer patients present with
disease which threatens or involves the potential mesorectal
surgical excision margin. These patients might be considered to
have ‘locally advanced inoperable’ disease with a high risk of local
recurrence unless some form of downstaging is carried out before
surgery. As an indication of what might be achieved in the modern
era using downstaging CRT with a single agent fluoropyrimidine as
a radiation sensitiser in patients with locally advanced carcinomas,
a single UK cancer network audit has been reported in 150 patients
with locally advanced rectal cancer (Mawdsley et al, 2005). Sixty-
one percent were T4 and approximately one-third had been staged
by MRI. Concurrent bolus 5-FU was administered in weeks 1 and 5
of radiotherapy as per the EORTC 22921 and FFCD 9203 trials. On
an intention to treat (ITT) analysis, an R0 resection was achieved
in only 65% of patients and the poor prognostic significance of
involved CRM post-downstaging CRT was confirmed with 3-year
local recurrence at 10 vs 62% and 3-year disease-free survival at
52 vs 9% for R0 vs R1/2 resections, respectively.
There is a need to improve on the potency of currently available
downstaging CRT regimes and one potential way of achieving this
is by adding in a second chemotherapy agent to form a doublet in
addition to a fluoropyrimidine. The topoisomerase-I inhibitor
irinotecan is one possible agent to use in this context in view of
radiosensitising properties demonstrated in vitro (Chen et al,
1997). Several early phase studies have been reported (Mehta et al,
2003; Klautke et al, 2005; Mohiuddin et al, 2006; Navarro et al,
2006; Glynne-Jones et al, 2007) including by our own group (Iles
et al, 2008) concerning rectal cancer CRT regimes using the
doublet of 5FU plus irinotecan as radiation sensitisers. Rates of
grade 3 or 4 toxicity have varied from between 12–37% (mostly
diarrhoea) with promising pathological complete response (pCR)
rates of between 14–37% for resected specimens.
There are potential advantages in using the oral 5FU prodrug
capecitabine rather than 5FU itself including the avoidance of
a central venous catheter to administer continuous infusional
5FU. In addition, the final enzymatic conversion of capecitabine is
mediated via thymidine phosphorylase which often occurs in a
higher concentration in cancer tissue compared with adjacent
normal tissue with the potential advantage of improving
the therapeutic ratio compared with 5FU (Glynne-Jones
et al, 2006). Thymidine phosphorylase is upregulated by RT
(Sawada et al, 1999).
This study represents a progression of previous research
reported by our group (the North West/North Wales Clinical
Oncology Group) which used irinotecan and infusional 5FU as a
doublet of concurrent radiation sensitisers in the preoperative
downstaging of locally advanced rectal cancer (Iles et al, 2008).
This study is a phase I trial in patients with MRI-defined locally
advanced rectal cancer which is threatening or involving the
mesorectal fascia and replaces the infusional 5FU with continuous
oral capecitabine. The doses of irinotecan and capecitabine were
gradually increased, keeping the radiation dose constant, with
toxicity being the primary end point.
PATIENTS AND METHODS
Inclusion criteria
Male or female patients aged X18 years old, of WHO performance
status 0, 1 or 2 were included. All had provided written informed
consent to participate in the trial. Patients had histologically
confirmed previously untreated carcinoma of the rectum with
the distal extent within 12cm of the anal verge using a rigid
sigmoidoscope. They were deemed to be a candidate for
preoperative downstaging chemoradiation due to T3 disease on
MRI scanning p1mm from the edge of the mesorectum or T4
disease on MRI scanning or any T3/T4 disease on MRI scanning
with the distal extent of tumour p5cm from the anal margin. Any
nodal status (N0-2) was permitted and computerised tomography
(CT) scanning of abdomen and pelvis had failed to detect evidence
of metastatic (M1) disease. All radiological investigations were to
be carried out within 4 weeks of trial registration. Patients had
adequate haematology with a neutrophil count 41.5 10
9l
 1,
platelet count 4100 10
9l
 1,H b 49gdl
 1 (the use of blood
transfusions was allowed to increase the level of haemoglobin).
Patients also had adequate renal and hepatic function with serum
creatinine p1.5 ULN, serum bilirubin p1.25 ULN, serum
ALT, AST and alkaline phosphatase p2.5 ULN.
Exclusion criteria
Any of the following was regarded as a criterion for exclusion from
the trial: previous systemic chemotherapy; previous radiotherapy
to the planned exposure area; any severe concurrent medical
condition which would make it undesirable, in the supervising
clinician’s opinion, for the patient to participate in the trial or
which would jeopardise compliance with the trial protocol;
a calculated creatinine clearance of less than 50mlmin
 1; loss of
continuity of the upper GI tract or malabsorption; a history of
myocardial infarction within previous year and/or with unstable
angina, arrythmia or cardiac failure; pregnancy or lactation;
patients of child-bearing potential not implementing adequate
contraception; previous or current malignancies at other sites, with
the exception of adequately treated in situ carcinoma of the cervix
uteri and basal or squamous cell carcinoma of the skin; subjects
considered by the investigator to be at risk of transmitting any
infection through blood or other body fluid including acquired
immune deficiency syndrome, or other sexually transmitted
disease or hepatitis; participation in other clinical trials; partial
or complete bowel obstruction (though patients in whom this had
been relieved with a defunctioning stoma, were permitted to enter
the trial).
Study structure
The primary objective of the study was to determine the maximum-
tolerated dose (MTD) of intravenous irinotecan and capecitabine
when given concurrently with long-course preoperative pelvic
radiotherapy in patients who have locally advanced rectal cancer.
The regime defined using the MTD of capecitabine and irinotecan
could then be taken forward into a future phase II trial.
Patients were treated with a 5-week course of downstaging CRT.
The dose of radiotherapy was fixed at 45Gy and the aim was to
gradually increase the doses of capecitabine and irinotecan in
cohorts of three patients until the MTD had been defined. An
MRI scan was carried out 6 weeks following CRT and surgery
attempted 2 weeks following the MRI scan, that is, 8 weeks
following completion of CRT. Acute toxicity was assessed weekly
throughout the 5-week course of CRT then weekly for 4 weeks
afterwards. Postoperative morbidity was assessed up to 30 days
post surgery. Late toxicity was assessed at 6, 12, 24 and 36 months
post completion of CRT.
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RT was planned with patients in the prone position with a full
bladder (depending on patient tolerance) and an anal marker.
Either CT or fluoroscopic simulation (with rectal barium contrast)
were acceptable for planning RT. Opacification of the small bowel
was recommended (e.g., 300ml Baritop plus 20ml Gastrograffin
orally 45–60min before simulation). A belly board was not
routinely used.
A Gross Tumour Volume (GTV) was defined using clinical
evidence and pelvic radiological imaging. The Planned Target
Volume (PTV) was defined as follows. Superiorly 3cm superior to
the most superior extent of the GTV, but PTV to extend no higher
than the sacral promontory. Inferiorly 3cm inferior to the most
inferior extent of GTV. Posteriorly the border of the most posterior
aspect of sacrum. Anteriorly 2cm anterior to tumour or the
anterior rectal wall whichever is the more anterior. Laterally 3cm
lateral to the most lateral extent of GTV.
RT was prescribed to the central axis of the beams. In the central
axis section, the dose within the target area was stipulated to be no
less than 95% and no more than 105% of the prescribed dose.
Treatment was to 45Gy in 25 daily fractions over 5 weeks, treating for
5 days (Monday–Friday) per week at 1.8Gy per day. Three or four
treatment fields were allowed and all fields were to be treated daily.
Chemotherapy
The haematologic and serum biochemical parameters outlined in
‘Inclusion Criteria’ (above) had to be confirmed within the week
before commencing study treatment.
Capecitabine was taken continuously throughout the 5-week
course of radiotherapy including weekends. The capecitabine
tablets were taken twice daily approximately 12h apart within
30min of the ingestion of food (ideally after breakfast and evening
meal) with approximately 200ml of water (not fruit juices), and
before radiotherapy on day 1. Irinotecan was given as a 60min
intravenous infusion in 250ml of normal saline once per week
during weeks 1, 2, 3 and 4 of radiotherapy (with equal, weekly
spacing between infusions). There was flexibility as to which day in
the week was chosen to administer irinotecan.
The starting dose (dose level 1) of capecitabine was 650mgm
 2
b.i.d. and irinotecan 50mgm
 2. The doses were then gradually
escalated as follows: dose level 2: capecitabine 650mgm
 2 b.i.d.
and irinotecan 60mg/m
2; dose level 3: capecitabine 825mg/m
2
b.i.d. and irinotecan 60mg/m
2; dose level 4: capecitabine 825mg/
m
2 b.i.d. and irinotecan 70mg/m
2.
It was planned that there would be three patients per cohort.
Toxicity was assessed until 4 weeks post completion of radiotherapy
that is, 9 weeks in total. If no dose-limiting toxicity (DLT) was
encountered, further patients would be entered at the next higher
dose level. The next dose level was not available to recruitment until
toxicity data was available for the whole 9-week period for all
patients on a particular dose level. If one patient developed grade 3/
4 toxicity, then a further three patients would be added to that
cohort. If there were no further episodes of grade 3/4 toxicity (i.e.,
one of six patients showed a DLT), then further patients would be
entered at the next higher dose level. If at least two out of six
patients at the same dose level developed DLT, then this was to be
considered as too toxic and the next three patients were treated at
the dose level lower. The highest dose level at which zero of three or
one of six patients developed DLT was considered the MTD. It was
the intention to use the CRT regimen at the MTD in a subsequent
phase II trial in an expanded number of patients (100).
Acute toxicity assessment and dose adjustment
Toxicity was scored according to the National Cancer Institute
Common Toxicity Criteria version 2.0 (published 30 April 1999).
DLT was defined as: grade 3 or 4 diarrhoea; grade 3 or 4 fatigue;
grade 3 or 4 neutropenia accompanied by fever (4381C) or
Xgrade 3 infection; grade 4 thrombocytopenia; grade 4 nausea/
vomiting despite full antiemetic treatment; grade 3 palmar–
plantar erythrodysesthesia (Hand Foot Syndrome); dose delay of
42 weeks because of drug-related toxicity.
If grade 1 haematological toxicity was encountered no adjust-
ment of RT or chemotherapy took place. For grade 2 haemato-
logical toxicity no adjustment of radiotherapy took place but
chemotherapy was interrupted until grade 0–1 then continued at
100% dose. For grade 3 haematological toxicity RT was interrupted
until grade 0–1 then continued and chemotherapy interrupted
until grade 0–1 then continued at 75% dose. For grade 4
haematological toxicity RT was interrupted until grade 0–1 then
continued and chemotherapy discontinued permanently.
If grade 1 non-haematological toxicity was encountered no
adjustment of RT or chemotherapy took place. For grade 2
non-haematological toxicity daily review of RT took place but
chemotherapy was interrupted until grade 0 then continued at
100% dose. For grade 3 non-haematological toxicity daily review of
RT took place and chemotherapy interrupted until grade 0 then
continued at 75% dose. For grade 4 non-haematological toxicity
RT was discontinued unless toxicity settled to grade 0–1 within
2 weeks when it could be continued and chemotherapy was
discontinued permanently.
Surgery and histopathological examination of the resected
specimen
A defunctioning stoma was permitted before CRT if judged
clinically necessary because of intolerable pelvic symptoms. Total
mesorectal excision was used for surgical resection. Histopatho-
logical examination of surgically resected specimens (including
India inking of the CRM) was carried out according to minimum
data set guidelines issued by the UK Royal College of Pathologists
(Quirke and Williams, 1998).
Study conduct
The study had full UK Multicentre Research Ethics Committee
approval (MREC/04/4/015), Clinical Trials Authorisation from
the Medicines and Healthcare Regulatory Agency for the use
of irinotecan (MF 8000/12694) and capecitabine (MF 8000/12695)
and was overseen by an Independent Data Safety Monitoring
Committee. It was conducted according to European Clinical Trials
Directive 2001/20/EC and sponsored by Conwy and Denbighshire
NHS Trust. It was included on the UK National Cancer Research
Network portfolio (NCRN Trial ID: 1387). The trial was conducted
in accordance with The Declaration of Helsinki and Good Clinical
Practice Guidelines.
Statistics
Kaplan–Meier censored survival curves were used, plotted with
regard to the 46 patients in the intent-to-treat population. Disease-
free survival was defined as the first event of local pelvic
recurrence, distant metastases or death.
RESULTS
Patient characteristics
Between September 2003 and June 2005 a total of 47 patients
consented to participation in the trial of which 46 commenced
treatment (one patient withdrew consent before starting treat-
ment). Details of patients and tumour characteristics are shown in
Table 1. Five patients had a defunctioning stoma before treatment.
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Details of toxicity at the various dose levels are illustrated in
Table 2. The most common grade 3 toxicity was diarrhoea
(recorded overall in 10 patients), Other grade 3 toxicities (some
overlapping), which occurred included fatigue (three patients),
anorexia (two patients), uncomplicated neutropenia (three
patients), neutropenic fever (two patients), nausea/vomiting (two
patients), palmar–plantar erythrodysesthesia (PPE) (one patient),
abnormal liver enzymes (one patient) and hypertension (one
patient).
At dose level 1 there were no dose-limiting toxicities and thus
the trial progressed to dose level 2.
One of the first three patients on dose level 2 developed a
protocol-stipulated DLT (grade 3 diarrhoea) and thus three
additional patients were added on this dose level with no further
DLTs. Progression was then made to dose level 3.
Owing to an administrative error, seven patients were initially
treated at dose level 3. One of these suffered a DLT (grade 3
fatigue). One other patient, a 72-year-old female, who had been
well, presented with an acute neurological event on day 22 of
therapy, characterised by almost complete dysphagia, marked
drowsiness and nausea suggesting a possible brain stem cerebro-
vascular accident although this was not confirmed on an MRI scan.
No further chemotherapy was given although she went on to
complete her RT after an 8-day delay with a subsequent slow
neurological recovery over the following 2 months. There was
uncertainty as to the nature of this episode, particularly in view of
the fact that she did not show other anticipated treatment-related
toxicities (no diarrhoea, neutropenia or dehydration) and in view
of this progression was then made to dose level 4.
On dose level 4, two of six patients experienced DLT (grade 3
diarrhoea and neutropenic fever) and thus the trial stepped down a
dose level back to dose level 3 as the provisional initial
recommended dose for expanding out for treatment of an
increased number of patients.
Of the first additional 16 patients treated at dose level 3 however,
seven developed a DLT. This meant that a total of 8 of 23 patients
(34%) treated on dose level 3 had developed at least one DLT
(Table 3).
After review of the data by the Independent Data Safety
Monitoring Committee, dose level 2 was chosen as the revised
recommended dose at which to include further patients. A further
eight patients were then treated at dose level 2 of which two
developed a DLT (grade 3 diarrhoea). Thus in total, 3 of 14 patients
(21%) at dose level 2 developed a DLT, which was considered
acceptable as a recommended dose to use in future studies.
The consort flowchart showing the flow of patients through the
study is shown in Figure 1. Of the 46 patients who commenced
treatment, five (11%) did not undergo surgical resection and their
details are as follows.
A 68-year-old female patient (dose level 3) had been well until
week 4 of treatment, being admitted as an emergency on day 28 of
her treatment course. She experienced a rapid onset of diarrhoea
and on admission was dehydrated with grade 3 PPE, grade 3
neutropenia, marked mucositis and hypoalbuminaemia. She was
treated with full supportive measures including intravenous
rehydration and broad spectrum antibiotics but her condition
continued to deteriorate, resulting in her death from pneumonia a
week post admission. A 59-year-old male patient (dose level 3)
developed liver metastases on re-staging. A 73-year-old male
patient (dose level 3) completed CRT but was found to have
unresectable disease on re-staging. A 65-year-old male patient
(dose level 2) completed CRT but suffered a gradual deterioration
in general condition, which meant that he was never fit for
resection, dying approximately a year later. Finally, a 66-year-old
female patient developed a recto-vaginal fistula during CRT,
completing only 19 fractions of radiotherapy. She experienced a
rapid deterioration in her general condition resulting in death.
One male patient (dose level 3) developed intraoperative
bleeding and had a cardiac arrest and died on the operating table,
immediately following resection of his cancer.
Overall 5 of 13 females (38%) developed a grade-3 toxicity
compared with 8 of 33 males (24%) although this difference was
not significant using w
2 (P¼0.55).
Dose intensity that was achieved, expressed in terms of the
average percentage of the total intended dose that could be
delivered at each dose level is shown in Table 4. At all dose levels at
least 96% of the intended dose of RT was able to be delivered and
at least 93% of the intended dose of irinotecan. However, the
achievable dose intensity of capecitabine was lower with only 82%
deliverable at dose levels 3 and 4. At the eventual recommended
dose level 2, the achievable dose intensities were: RT 100%,
irinotecan 96% and capecitabine 91%.
MRI post chemoradiation
Forty-three patients had a second MRI post CRT. Three patients
did not have a second MRI because of death during CRT of one
patient, development of a recto-vaginal fistula during CRT in one
patient with rapid clinical deterioration then death and patient
refusal in a third (subsequently resected with a negative CRM).
Comparing pre- vs post-CRT MRI scans (Table 5), 18 patients
(42%) were judged to have had their T-stage downstaged, 25 (58%)
unchanged and none upstaged. None of nine patients with N0
Table 1 Baseline patient and tumour characteristics
Gender Number (%)
Male 33 (72)
Female 13 (28)
WHO PS
Number of
patients (%)
0 37 (80)
1 8 (17)
2 1 (2)
Age: median 61.5 years (range, 34–78 years)
Distance from distal tumour margin to anal verge using rigid sigmoidoscope:
Median 7.0cm (range, 0–12.0cm)
Location
Number of
patients (%)
0–5cm 12 (26)
45–10cm 30 (65)
410–12cm 4 (9)
Local stage (MRI)
Number of
patients (%)
T3 38 (83)
T4 8 (17)
N0 10 (22)
N1 26 (56)
N2 10 (22)
Relation of primary tumour to mesorectum (MRI)
Mesorectal fascia not involved
a 4
Mesorectal fascia potentially involved (p1mm from
primary tumour) (n)
15
Mesorectal fascia involved but not breached by primary
tumour) (n)
12
Mesorectal fascia breached (n)1 5
aLow third cancers p50mm from anal verge, one with definite involvement of
external anal sphincter.
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who had had N1 or N2 disease on their pre-CRT MRI scan,
30 (88%) were judged to have had their N stage downstaged, four
(12%) unchanged and none upstaged.
Surgery
The median time between the last fraction of RT and surgery
was 59 days (range 41–118 days). 41 patients underwent resection:
three of three included at dose level 1, 13 of 14 at dose level 2,
20 of 23 at dose level 3 and five of six at dose level 4. Thirty-one
patients underwent an anterior resection, nine an abdomino-
perineal resection and one a Hartman’s procedure. Twenty-two of
the 31 patients having an anterior resection had a defunctioning
stoma (17 ileostomy and five colostomy). Postoperatively the
median inpatient stay was 11 days (range, 6–42 days).
The postoperative complications prospectively recorded as
occurring within 30 days of surgery are shown in Table 6. Of the
40 patients who underwent resection and were alive postopera-
tively none died within the 30-day postoperative period. There
were 7 pelvic or wound infections and two anastomotic and two
perineal wound dehiscences.
Histology
Of 41 resected specimens, 11 (27%) showed a pathological
complete response (pCR; T0), two (5%) were T1, four (10%) T2,
23 (56%) T3 and one (2%) T4. Thirty-three (80%) were N0, five
(12%) N1 and three (7%) N2. The average nodal yield was 14 per
specimen (range, 2–43). Numbers of patients showing a pCR/
number of resected specimens at each dose level were as follows:
1/3 at dose level 1, 6/13 at dose level 2, 3/20 at dose level 3 and 1/5
Table 2 Worst toxicity grade and incidence according to dose levels during chemoradiation and up to 4 weeks afterwards (numbers of patients for each
toxicity level shown)
Dose level
1 n¼32 n¼6+8¼14 3 n¼7+16¼23 4 n¼6
Toxicity grade NCI CTC 1234 1234 1234 1 2 3 4
Haematologic
Anaemia 2 4 3 5 1
Leukopenia 1 3 1 3 2
Thrombopenia 1
Neutropenia 1 1 3 1 3 1 1
Haemorrhage 1 1
Infective
Non-neutropenic fever/infection (ANCX1.0 10
9 1)1 3 1 1 1
Neutropenic fever/infection (ANCo1.0 10
9l
 1)11 1
Biochemical
Hyperbilirubinaemia 1 2 7 1
AST/ALT 4 3 1
Creatinine elevation 1 1
Gastrointestinal
Stomatitis 2 4 1
Nausea/vomiting 2 2 3 2 1
Diarrhoea 2 2 4 3 6 1
Cholinergic syndrome 31
Constitutional
Fatigue/lethargy 2 4 6 3 2
Anorexia 2 3 2 2 1
Weight loss 2 1 4 1
Dermatology
Palmar plantar erythrodysesthesia (PPE) 1 1 2 1 1
Alopecia 42
Skin (radiation dermatitis) 1 3 2 2 2
Cardiac
Hypertension 1
Hypotension 1 2
Cardiac function 1
Table 3 Number of patients at each dose level who experience the
specified number of dose-limiting toxicities
Dose level
Number of DLTs per
patient
1
n¼3
2
n¼6+8¼14
3
n¼7+16¼23
4
n¼6
1— 3 4 2
2— — 3 —
3— — 1 —
Total number of patients
experiencing at least one DLT
0/3 3/14 8/23 2/6
Rectal cancer irinotecan/capecitabine chemoradiation
SW Gollins et al
928
British Journal of Cancer (2009) 101(6), 924–934 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sat dose level 4. Ten patients (24%) had only microfoci of disease
remaining (2 T1, 3 T2, 5 T3, 9 N0 and 1 N1).
Overall 36 of the 41 specimens (88%) showed a histologically
clear CRM (R0 resection) and five (12%) an involved CRM
(defined as p1mm). Three out of 26 patients whose RT was
planned using fluoroscopy were CRM positive compared to 2
of 20 patients who underwent CT planning (P¼0.76 by w
2). Two
of the five CRM-positive patients were in the low rectum,
two mid and one upper and the post-CRT MRI predicted
involvement in three of the five cases. Three CRM-positive
cases were predominantly anterior and two predominantly
posterior.
Comparing pre-CRT MRI scans with histology of the resected
specimen (Table 7), 20 patients (49%) had their T-stage down-
staged and one (2%) upstaged. Twenty-five of 32 initial MRI N1-2
patients (78%) had their N stage downstaged and all of nine initial
MRI N0 patients were N0 on resection.
Long-term clinical outcome
Although not formally the end point of this phase I trial, the
median length of follow-up of patients was 41.2 months, which
presented an opportunity to examine longer-term outcomes. For
the whole group of 46 patients the 3-year overall survival was
68.5% (Figure 2), disease-free survival 53.2% (Figure 3), pelvic
disease-free survival 88.3% (Figure 4) and distant metastasis-free
survival 67.0% (Figure 5). Of the 40 patients whose tumour was
resected and were alive immediately postoperatively, two deve-
loped a local pelvic recurrence at 9 and 13 months post surgery. In
all, 13 patients developed distant metastatic disease.
None of the five histologically CRM-positive cases developed
locally recurrent disease on follow-up although two developed
distant metastases, dying at 24 and 58 months. Of the other three
CRM-positive patients, one died at 20 months of other causes and
two were alive and well when last seen at 40 and 47 months.
DISCUSSION
This study is a phase I study examining the combination of
irinotecan and capecitabine as concurrent radiation sensitisers in
the downstaging CRT of locally advanced rectal cancer before
attempting surgery. Among studies examining this CRT regimen
Consort flowchart of flow of patients through the NWCOG-2 phase I trial
from recruitment to 30 days post operative
Forty seven patients consented to enter the trial 
CRT: Dose level 1 n = 3, Dose level 2  n = 14, Dose level 3 n = 23, Dose level 4 n = 6
One patient withdrew consent before
starting treatment
One patient died following resection but during 
surgery
Five patients did not undergo surgical resection:
One patient died during CRT, clinical severe fluoropyrimidine
toxicity (dose level 3)
One patient developed distant metastases on restaging (dose level 3) 
One patient completed CRT but disease unresectable on restaging 
(dose level 3)
One patient completed CRT then general condition gradually 
deteriorated  (dose level 2)
One patient completed 19 fractions of RT only, developed 
rectovaginal fistula and rapidly deteriorated (dose level 4)
Forty resected surviving patients 
immediately post op
Forty one patients underwent 
surgical resection
No further deaths within the 
first 30 days post op
Figure 1 Consort flowchart of flow of patients through the NWCOG-2 phase I trial from recruitment to 30 days post operative.
Table 4 Dose intensity: Mean percentage of intended dose of
radiotherapy, capecitabine and irinotecan that was delivered at each dose
level
Dose
level 1
Dose
level 2
Dose
level 3
Dose
level 4
Patients per cohort 3 14 23 6
RT completed (%) 100 100 96 96
Irinotecan completed (%) 100 96 94 93
Capecitabine completed (%) 99 91 82 82
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sthis study is unique in using MRI scanning as an inclusion criteria
to show threatening or involvement of the mesorectal fascial
excision plane by the primary tumour. MRI scanning is now
regarded as the investigation of choice in staging rectal cancers
with regard to this feature and judgment of operability or not,
meaning that rectal cancers included in this study can be more
confidently staged as ‘locally advanced inoperable’ than other
studies hitherto published using this CRT regimen (Hofheinz et al,
2005; Klautke et al, 2006, 2007; Willeke et al, 2007) (Table 8). These
have predominantly used trans-rectal ultrasound (TRUS) and CT
scanning for staging, with no requirement for MRI staging. The
poor-risk nature of the patients in our study was confirmed by the
53.2% 3-year DFS (Figure 3).
In keeping with the above previously reported studies the
predominant DLT encountered in this study was diarrhoea, with
lesser degrees of fatigue, neutropenic sepsis, anorexia and PPE. No
patient developed grade 4 diarrhoea and at our recommended dose
level 2 of capecitabine 650mgm
 2 b.i.d. days 1–35 and irinotecan
60mgm
–2 once per week during weeks 1, 2, 3 and 4 combined
Table 6 Immediate post-operative complications (within 30 days of
surgery) within the 40 patients undergoing resection and alive post
operatively
Post-operative complication Number of patients
Pelvic infection 4 (one with peritonitis also)
Wound infection 3
Serious infection elsewhere 2 (chest, urinary)
Anastomotic dehiscence 2
Perineal wound dehiscence 2
Re-catheterisation necessary 1
Haemorrhage within the operative field
necessitating return to theatre
0
Venous thromboembolic event 0
Myocardial infarction 0
Cerebrovascular accident 0
Ventilation needed for 424h postop 0
Acute respiratory distress syndrome 0
Death 0
Median time spent on ITU/HDU post op in
days (range)
0 (0–14)
Readmission necessary after discharge 5
a
Other serious post-operative complications 4: (Atrial fribrillation)
(Enteral feeding required)
(Prolonged rectal drain)
(Neurogenic bladder)
aOne patient readmitted for femoral distal bypass following Hartmann’s procedure,
probably unrelated to rectal cancer treatment.
Table 5 Pre-treatment MRI scan stage compared with post-chemoradiation MRI stage n¼43
Post-chemoradiation MRI stage
T0 T1 T2 T3 T4 Total (%)
T3 3 0 13 20 0 36 (84)
T4 0 0 0 2 5 7 (16)
Total (%) 3 (7) 0 13 (30) 22 (51) 5 (12) 43 (100)
Pre-treatment MRI stage
N0 N1 N2 Total (%)
N0 9 0 0 9 (21)
N1 23 2 0 25 (58)
N2 6 1 2 9 (21)
Total (%) 38 (88) 3 (7) 2 (5) 43 (100)
Table 7 Pre-treatment MRI scan stage compared to histology of the
resected specimen (n¼41)
Histology of resected specimen
T0 T1 T2 T3 T4 Total (%)
T3 9 1 4 20 1 35 (85)
T4 2 1 0 3 0 6 (15)
Total (%) 11 (27) 2 (5) 4 (10) 23 (56) 1 (2) 41 (100)
Pre-treatment
MRI stage
N0 N1 N2 Total (%)
N0 9 0 0 9 (22)
N1 20 4 0 24 (59)
N2 4 1 3 8 (20)
Total (%) 33 (80) 5 (12) 3 (7) 41 (100)
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Figure 2 Overall survival (n¼46).
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swith an RT dose of 45Gy in 25 daily fractions over 5 weeks, we
recorded acceptable acute toxicity with 3 of 14 patients (21%)
developing grade 3 diarrhoea.
In the study by Hofheinz et al (2005) the recommended dose
was irinotecan at 50mgm
 2 once per week for five consecutive
weeks (250mgm
 2 total) plus capecitabine at 500mgm
 2 b.i.d. 7
days per week on days 1–38 throughout a course of RT delivering
50.4Gy in 1.8Gy fractions over 5.5 weeks. Only one of 12 patients
developed a serious toxicity (grade 3 fatigue). However, when the
dose of capecitabine was increased to 625mgm
 2 b.i.d., three of
seven patients developed grade 3 diarrhoea, one grade three
nausea and one grade three anorexia.
Willeke et al (2007) treated 36 patients with a similar regimen to
the recommended dose of Hofheinz et al (2005). Again, they found
a relatively low rate of grade 3 diarrhoea (11%) and fatigue (3%)
although 25% of patients had grade 3 or 4 leukopenia.
The recommended dose in the study by Klautke et al (2006)
delivered an identical overall irinotecan dose to that in this study
(240mgm
 2 total) although this was delivered in 6 rather than 4
weekly treatments. The recommended daily capecitabine dose at
750mgm
 2 b.i.d. was higher and delivered for a week longer
(continuously days 1–43) than that in this study. The radiation
dose was also 24% higher at 55.8Gy delivered in 31 daily fractions
over 6 weeks. At this dose level, however, 6 of 16 patients (38%)
developed grade 3 diarrhoea.
In view of the above, Klautke et al (2007) modified their
regimen, maintaining the same daily dose of capecitabine at
750mgm
 2 b.i.d. but giving this for a total of 4 weeks only (weeks
1, 2, 4 and 5) rather than for 6 weeks. In addition the total dose of
irinotecan delivered was reduced to 200mgm
 2, given in the same
4 weeks in which capecitabine was delivered (weeks 1, 2, 4 and 5).
In 20 patients this was well tolerated with 10% grade 3 diarrhoea
but no histological specimen showed a pCR. This then prompted
the use of an increased total irinotecan dose (to 240mgm
 2,i n
four treatment weeks 1, 2, 4 and 5) in a further 20 patients. The
rate of grade 3 diarrhoea increased slightly (to 15%) but seven
specimens (35%) now showed a pCR.
This study differs from the above initially in delivering a lower
dose of 45Gy of RT rather than 50.4–55.8Gy. In addition, smaller
volumes of tissue were irradiated in this study compared with
others with the maximum superior extent of the PTV at the sacral
promontory. It is likely that the predominant acute toxicity seen of
diarrhoea is largely caused by small bowel enteritis, partly because
of the chemotherapy element but also partly because of small
bowel in the radiation field. Klautke et al (2006) stipulated that the
superior border of the radiation field included the fifth lumbar
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Figure 3 Disease-free survival (n¼46).
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Figure 4 Local pelvic disease-free survival (n¼46).
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svertebral body and Hofheinz et al (2005) and Willeke et al (2007)
stipulated that the upper border of the clinical target volume
(CTV) was at L4–5 for cN-positive patients and the lower border
at 5cm below macroscopic tumour. It is noteworthy that the
superior field border had been reduced to the L5/S1 junction in the
later report of Klautke et al (2007), possibly contributing to the
reported reduction in acute toxicity.
We gave capecitabine continuously throughout RT including
weekends to mimic the continuous infusion 5FU that was used in
our previous study (Iles et al, 2008). At the recommended dose
level 2 in this study the overall dose of capecitabine delivered was
45500mgm
 2 compared to 38000mgm
 2 in Hofheinz et al (2005)
and Willeke et al (2007) and 64500mgm
 2 in Klautke et al (2006).
We found that the component of our CRT regimen that was
difficult to deliver in its entirety because of toxicity, as the dose
levels were increased was the capecitabine. At dose level 3 at which
a total dose of capecitabine of 57750mgm
 2 was intended to be
given, a mean of only 82% of the intended dose could be delivered
(Table 4). It is striking that Klautke et al (2007) needed to modify
their capecitabine to achieve acceptable toxicity. Whether this was
due to the two enforced weekly breaks or simply due to a reduction
in the overall delivered dose to 42000mgm
 2 is unclear.
In contrast to the other studies mentioned above, we adopted a
strategy of giving irinotecan weekly for the first 4 weeks of a 5-
week course of rectal CRT. This approach was similar to that used
in our previous study when irinotecan was combined with
continuous infusion 5FU throughout the course of RT (Iles et al,
2008). The rationale for this was to ‘front-load’ the irinotecan so
that a dose would not be delivered in the final fifth week when
diarrhoea was liable to be approaching its maximum. We found
that at all dose levels a mean of at least 93% of the intended dose of
irinotecan could be delivered.
Although not the primary end point of this study, the pCR rate
of 27% in resected patients (or 24% by ITT) is promising and lies
within the range of 15–35% reported by others (Table 8). The rate
of histologically clear surgical CRM reported in this study (88% of
resected specimens or 78% by ITT) is also encouraging, as is the
low pelvic recurrence rate (Figure 4).
It is likely that the toxicity and tumour response resulting from
the combination of a doublet of chemotherapy in addition to RT
are complex and dynamic processes with potential marked
resultant differences depending on the interplay of the chemother-
apy administration schedule and dose and the RT volume, timing,
dose and fractionation. The CRT regime (dose level 2) recom-
mended for taking forward into further studies in the current
report, would not be out of keeping with those recommended in
the other studies although there are significant differences as
outlined above. It may appear counter-intuitive to combine three
agents (RT, capecitabine, irinotecan) all of which have the
overlapping toxicity of diarrhoea although it does appear that at
the doses recommended in this study the incidence of this toxicity
at serious levels is acceptable. Indeed, at the doses recommended
by ourselves and others, rates of diarrhoea reported are not
dissimilar to those reported using the doublet of capecitabine plus
oxaliplatin as radiation sensitisers in this context (Glynne-Jones
et al, 2006).
The patient who died in this study on dose level 3 showed signs
of severe fluoropyrimidine toxicity. It may be that this patient had
a specific metabolic disorder such as dihydropyrimidine dehy-
drogenase deficiency increasing susceptibility to fluoropyrimidine
Table 8 Phase I/II studies of neoadjuvant rectal cancer CRT using concurrent capecitabine plus irinotecan
Author Phase
Total
no. of
subjects
Pelvic
staging
method
Clinical
stage RT dose
Capecitabine
dose
Irinotecan
dose
Grade 3/4
toxicity
PCR
rate
R0 resection
rate
Hofheinz et al
(2005)
I dose
escalation
19 TRUS
Pelvic CT
T3 n¼18
T4 n¼1
50.4Gy
28Fr
5.5 weeks
500mgm
 2
bd days 1–38
a
50mg/m
2
weekly  5
1/12 gr 3 fatigue 4 of 19
resected
¼21%
NS
625mgm
 2
bd days 1–38
50mg/m
2
weekly  5
3/7gr 3 diarrhoea
1/7gr 3 N+V
1/7gr 3 anorexia
1/7gr 3 leukopenia
Klautke et al
(2006)
I/II 28 TRUS
Pelvic CT
T2 n¼2
T3 n¼18
T4 n¼8
55.8Gy
31Fr
6 weeks
500mgm
 2
bd days 1–43
40mg/m
2
weekly  6
0/3 4 of 25
resected
¼15%
24/25 (96%)
650mgm
 2
bd days 1–43
40mg/m
2
weekly  6
0/3
750mgm
 2
bd days 1–43
a
40mg/m
2
weekly  6
6/16 (38%) gr 3
diarrhoea
825mgm
 2
bd days 1–43
40mg/m
2
weekly  6
3/6gr 3 diarrhoea
2/6gr 4 diarrhoea
1/6gr 3 HFS
1/6gr 3 leukopenia
Willeke et al
(2007)
II 36 TRUS
Pelvic CT
T2 n¼4
T3 n¼26
T4 n¼5
50.4Gy
28Fr
5.5 weeks
500mgm
 2
bd days 1–38
50mg/m
2
weekly  5
4/36 (11%) gr 3
diarrhoea
2/36gr 3 N+V
1/36gr 3 fatigue
7/36gr 3 leukopenia
2/36gr 4 leukopenia
5o f3 4
resected
¼15%
34/34 100%
Klautke et al
(2007)
II 20 TRUS
Pelvic CT
T3 n¼18
T4 n¼2
55.8Gy
31Fr
6 weeks
750mgm
 2
bd days 1–14,
22–35
50mg/m
2
weekly  4
(days 1, 8,
22, 29
2/10 (10%) gr 3
diarrhoea
0 20/20 100%
II 20 T2 n¼1
T3 n¼16
T4 n¼3
750mgm
 2
bd days 1–14,
22–35
60mg/m
2
weekly  4
(days 1, 8,
22, 29
3/20 (10%) gr 3
diarrhoea
7o f2 0
resected
¼35%
19/20 (95%)
Abbreviations: Day 1¼first day of RT; TRUS¼trans rectal ultrasound; N+V¼nausea and vomiting; NS¼not stated; HFS¼hand foot syndrome.
aRecommended dose.
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stoxicity although no specific testing for this was carried out. It
does, however, emphasise the importance of giving patients on
oral fluoropyrimidines clear advice that if they become unwell or
show signs of fluoropyrimidine toxicity, especially if these are
developing rapidly, then they must stop their tablets immediately
and ring promptly for medical advice. For patients receiving
aggressive treatment with a CRT regime such as that discussed in
this report, this is especially important.
When considering downstaging CRT for rectal cancer, toxicity
not only during CRT is important, but also expressed as
postoperative morbidity. Hofheinz et al (2005) reported that
of 19 resected patients, nine (47%) experienced a variety of
postoperative complications including wound dehiscence, bowel
atonia, bladder dysfunction, recto-vaginal fistula, a presacral
abscess needing drainage and anastomotic insufficiency and
complicated secondary wound healing requiring revision. There
were no intra- or postoperative deaths.
Willeke et al (2007), using a similar regimen to Hofheinz
et al (2005), reported that of the 34 operated patients nine (26%)
had prolonged or complicated wound healing, eight (24%) had
temporary bowel atonia, three (12%) developed an anastomotic
leakage and three (12%) an abscess. Two patients died post-
operatively from septic complications.
Klautke et al (2006) reported that of 25 operated patients there
was one anastomotic leakage and one bowel atonia treated conser-
vatively. There were, however, two deaths, one from pneumonia
and the other from sudden cardiac death. In their later report
(Klautke et al, 2007) no detailed report of postoperative
complications is presented other than to state that at the modified
dose discussed above, there were no postoperative deaths.
In this study there was one death due to intraoperative bleeding
and a consequent cardiac arrest in a patient on the operating table
who had had their rectal cancer resected. No cause for this was
found. In the 40 patients who underwent resection and were alive
postoperatively there were no deaths within the first 30 days and
postoperative morbidity (Table 6) did not appear to be unduly
severe.
In conclusion, we have developed a CRT regime for use in the
preoperative downstaging of locally advanced rectal cancer
incorporating the chemotherapy doublet of capecitabine and
irinotecan. This regime needs to be included in future studies in
larger numbers of patients to determine whether any advantage is
conferred compared with the use of a single agent fluoropyrimi-
dine as a radiation sensitiser in this context.
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